Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis.
It has a license agreement with Samil Pharma.
Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.
Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 1, 26 | 0.00 Increased by +100.00% | -0.51 Increased by +100.00% |
| Nov 26, 25 | -0.33 Increased by +85.70% | -0.79 Increased by +58.23% |
| Aug 28, 25 | -0.63 Increased by +70.47% | -0.83 Increased by +24.10% |
| May 22, 25 | -0.62 Increased by +36.73% | -0.89 Increased by +30.34% |
| Mar 26, 25 | -1.94 Decreased by -97.96% | - |
| Nov 20, 24 | -2.31 Decreased by -861.42% | - |
| Aug 23, 24 | -2.13 Decreased by -124.55% | - |
| May 30, 24 | -0.98 Increased by +10.09% | -0.32 Decreased by -206.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -1.89 M Increased by +1.15% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -2.50 M Decreased by -122.97% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -1.10 M Increased by +13.41% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -3.21 M Decreased by -59.18% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -1.91 M Decreased by -29.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.12 M Increased by +29.76% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.27 M Increased by +23.10% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.02 M Increased by +28.74% | Decreased by N/A% Decreased by N/A% |